Aim: To test the hypothesis that microdeletions or microduplications below the resolution of a standard karyotype may be a significant cause of highly skewed X-inactivation (HSXI) in women without a cytogenetically detected X-chromosome anomaly. Methods: Cases were women with HSXI, defined as ≥85% of cells in a blood sample with the same active allele at the HUMARA locus. The skewing in controls ranged from 50 to <75%. We performed an SNP microarray analysis using the Affymetrix 6.0 platform for 45 cases and 45 controls. Results: Cases and controls did not differ in the frequency of X-chromosome copy number changes ≥100 kb or in the frequency of copy number changes that contained genes. However, one woman with HSXI >90% in blood and left and right buccal smears had a 5.5-Mb deletion in Xp22.2p22.1. This deletion could affect the viability of male conceptions and may have led to the dysmorphology found in female carriers. Conclusion: HSXI in a blood sample is rarely due to X-chromosome copy number changes detectable by microarray.

Keywords:
Copy number changes, Microarray, Skewed X-inactivation
1.
Amos-Landgraf JM, Cottle A, Plenge, RM, Friez M, Schwartz CE, et al: X chromosome-inactivation patterns of 1,005 phenotypically unaffected females. Am J Hum Genet 79:493–499 (2006).
2.
Beever CL, Stephenson MD, Penaherrera MS, Jiang RH, Kalousek DK, et al: Skewed X-chromosome inactivation is associated with trisomy in women ascertained on the basis of recurrent spontaneous abortion or chromosomally abnormal pregnancies. Am J Hum Genet 72:399–407 (2003).
3.
Bolduc V, Chagnon P, Provost S, Dubé MP, Belisle C, et al: No evidence that skewing of X chromosome inactivation patterns is transmitted to offspring in humans. J Clin Invest 118:333–341 (2008).
4.
Brown LY, Alonso ML, Yu J, Warburton D, Brown S: Prenatal diagnosis of a familial Xq deletion in a female fetus: a case report. Prenat Diagn 21:27–30 (2001).
5.
Carrel L, Willard HF: X-inactivation profile reveals extensive variability in X-linked gene expression in females. Nature 434:400–404 (2005).
6.
Fialkow PJ: Primordial cell pool size and lineage relationships of five human cell types. Ann Hum Genet 37:39–48 (1973).
7.
Gale RE, Wheadon H, Boulos P, Linch DC: Tissue specificity of X-chromosome inactivation patterns. Blood 83:2899–2905 (1994).
8.
Hogge WA, Prosen TL, Lanasa MC, Huber HA, Reeves MF: Recurrent spontaneous abortion and skewed X-inactivation: is there an association? Am J Obstet Gynecol 196:384 e381–386; discussion 384 e386–388 (2007).
9.
Jobanputra V, Sebat J, Troge J, Chung W, Anyane-Yeboa K, et al: Application of ROMA (representational oligonucleotide microarray analysis) to patients with cytogenetic rearrangements. Genet Med 7:111–118 (2005).
10.
Kindich R, Florl AR, Jung V, Engers R, Müller M, et al: Application of a modified real-time PCR technique for relative gene copy number quantification to the determination of the relationship between NKX3.1 loss and MYC gain in prostate cancer. Clin Chem 51:649–652 (2005).
11.
Lanasa MC, Hogge WA, Kubik CJ, Blancato J Hoffman EP: Highly skewed X-chromosome inactivation is associated with idiopathic recurrent abortion. Am J Hum Genet 65:252–254 (1999).
12.
Lau AW, Brown CJ, Penaherrera M, Langlois S, Kalousek DK, Robinson WP: Skewed X-chromosome inactivation is common in fetuses or newborns associated with confined placental mosaicism. Am J Hum Genet 61:1353–1361 (1997).
13.
Migeon BR: Non-random X chromosome inactivation in mammalian cells. Cytogenet Cell Genet 80:142–148 (1998).
14.
Pergeraro E, Whitaker J, Mowery-Rushton P, Surti U, Lanasa M, Hoffman EP: Familial skewed X inactivation: a molecular trait associated with high spontaneous abortion rate maps to Xq28. Am J Hum Genet 61:160–170 (1997).
15.
Plenge RM, Hendrich BD, Schwartz C: A promoter mutation in the XIST gene in two unrelated families with skewed X-chromosome inactivation. Nat Genet 17:353–356 (1997).
16.
Redonnet-Vernhet I, Ploos van Amstel JK, Jansen RP, Wevers RA, Salvayre R, Levade T: Uneven X inactivation in a female monozygotic twin pair with Fabry disease and discordant expression of a novel mutation in the alpha-galactosidase A gene. J Med Genet 33:682–688 (1996).
17.
Schmidt M, Du Sart D, Kalitsis P, Fraser N, Leversha M, et al: X chromosome inactivation in fibroblasts of mentally retarded female carriers of the fragile site Xq27.3: application of the probe M27 beta to evaluate X inactivation status. Am J Med Genet 38:411–415 (1991).
18.
Schroder W, Wulff K, Wollina K, Herrmann FH: Haemophilia B in female twins caused by a point mutation in one factor IX gene and nonrandom inactivation patterns of the X-chromosomes. Thromb Haemost 78:1347–1351 (1997).
19.
Sharp A, Robinson D, Jacobs P: Age- and tissue-specific variation of X chromosome inactivation ratios in normal women. Hum Genet 107:343–349 (2000).
20.
Uehara S, Hashiyada M, Sato K, Sato Y, Fujimori K, Okamura K: Preferential X-chromosome inactivation in women with idiopathic recurrent pregnancy loss. Fert Steril 76:908–914 (2001).
21.
Warburton D, Kline J, Kinney A, Yu CY, Levin B, Brown S: Skewed X chromosome inactivation and trisomic spontaneous abortion: no association. Am J Hum Genet 85:179–193 (2009).
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.